Table 2 Cox regression model on the endpoint overall survival.

From: Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia

 

HR

95% CI

p value

Treatment Arm—ATRA

1.42

0.99–2.03

0.056

ECOG performance status > 1

1.14

0.78–1.66

0.501

HCTCI risk category > 2

1.52

1.05–2.20

0.025

Age (10 year difference)

1.59

1.10–2.29

0.013

WBC (ten-fold increase)

1.50

1.10–2.05

0.011

FLT3-ITD

1.18

0.79–1.77

0.417

  1. ATRA all-trans retinoic acid, ECOG Eastern Cooperative Oncology Group, HCTCI hematopoietic cell transplantation comorbidity index, WBC white blood count, FLT3-ITD fms-like tyrosine kinase internal tandem duplication.
Back to article page